Literature DB >> 29451017

Assessing Quality Control Strategies for HbA1c Measurements From a Patient Risk Perspective.

Curtis A Parvin1, Nikola A Baumann2.   

Abstract

BACKGROUND: Current laboratory risk management principles emphasize the importance of assessing laboratory quality control (QC) practices in terms of the risk of patient harm. Limited practical guidance or examples on how to do this are available.
METHODS: The patient risk model described in a published laboratory risk management guideline was combined with a recently reported approach to computing the predicted probability of patient harm to produce a risk management index (RMI) that compares the predicted probability of patient harm for a QC strategy to the acceptable probability of patient harm based on the expected severity of harm caused by an erroneously reported patient result.
RESULTS: Measurement procedure capability and quality control performance for two instruments measuring HbA1c in a laboratory were assessed by computing the RMI for each instrument individually and for the laboratory as a whole.
CONCLUSIONS: This assessment provides a concrete example of how laboratory QC practices can be directly correlated to the risk of patient harm from erroneously reported patient results.

Entities:  

Keywords:  patient risk; performance assessment; quality control; risk management

Mesh:

Substances:

Year:  2018        PMID: 29451017      PMCID: PMC6134296          DOI: 10.1177/1932296818758768

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  3 in total

1.  Should I repeat my 1:2s QC rejection?

Authors:  Curtis A Parvin; Lakshmi Kuchipudi; John C Yundt-Pacheco
Journal:  Clin Chem       Date:  2012-02-22       Impact factor: 8.327

Review 2.  8. Pharmacologic Approaches to Glycemic Treatment.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

3.  Assessing the impact of the frequency of quality control testing on the quality of reported patient results.

Authors:  Curtis A Parvin
Journal:  Clin Chem       Date:  2008-10-16       Impact factor: 8.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.